Regulatory Requirements for Drug Development and Approval in United States: A Review Rawat Swati1,*, Gupta Akhilesh2 1Shri Bhagwan College of Pharmacy, Aurangabad (M.S.) 2Kunwar Haribansh Singh College of Pharmacy, Jaunpur (U.P.) *Corresponding Author E-mail: swati_r@k.st
Online published on 19 June, 2014. Abstract In this paper a brief history and an overview of the regulatory process for drug approval in the United States through illustrations of Investigational New Drug (INDs) Applications and New Drug Applications (NDAs), abbreviated new drug applications (ANDAs) and supplemental new drug applications (SNDAs) are provided. For INDs, the regulatory requirements for a well-designed protocol, the role and responsibility of institutional review boards, and the applicability of treatment INDs are discussed. For NDAs, issues regarding the application of expanded access, the submission of abbreviated NDAs for a generic drug, the submission of supplemental NDAs for labeling changes, and the role and responsibility of advisory committees are addressed. Along with this a brief description of review steps taken by FDA is provided. Top Keywords Investigational New Drug Application, New Drug Application, International Conference on Harmonization. Top |